FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Frank Bymaster

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Drug Dose Response Relationship

Procedures

Anatomy

Brain

Co-author Network

Publications

TOP 3
Himanshu P Upadhyaya; Warren K Bickel; Frank P Bymaster; David O Calligaro; David O Clarke; Durisala Desaiah; Todd M Durell; Paul J Emmerson; MJ Kallman; Eric S Nisenbaum; Kory J Schuh; Leslie M Schuh; Paula T Trzepacz; Albert J Allen
A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.
Frank P Bymaster; Yong Kee Choi; Krystyna Golembiowska; Magdalena Kowalska; Frank I Tarazi
Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.
Krystyna Golembiowska; Magdalena Kowalska; Frank P Bymaster
Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Frank Bymaster (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Himanshu P Upadhyaya; Warren K Bickel; Frank P Bymaster; David O Calligaro; David O Clarke; Durisala Desaiah; Todd M Durell; Paul J Emmerson; MJ Kallman; Eric S Nisenbaum; Kory J Schuh; Leslie M Schuh; Paula T Trzepacz; Albert J Allen
A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.
Psychopharmacology 2013;226(2):189-200.
2012: Frank P Bymaster; Yong Kee Choi; Krystyna Golembiowska; Magdalena Kowalska; Frank I Tarazi
Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.
Synapse (New York, N.Y.) 2012;66(6):522-32.
2012: Krystyna Golembiowska; Magdalena Kowalska; Frank P Bymaster
Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.
Synapse (New York, N.Y.) 2012;66(5):435-44.
2012: David L McKinzie; Frank P Bymaster
Muscarinic mechanisms in psychotic disorders.
Handbook of experimental pharmacology 2012;(213):233-65.
2008: Nicholas M Wallingford; Puspha Sinnayah; Frank P Bymaster; Kishore M Gadde; Ranga K Krishnan; Anthony A McKinney; Ronald P Landbloom; Gary D Tollefson; Michael Alexander cowley
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(12):2922-33.
2008: Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
Pharmacological reviews 2008;60(3):358-403.
2008: W Y Chan; David L McKinzie; S Bose; S N Mitchell; Jeffrey M Witkin; R C Thompson; A Christopoulos; S Lazareno; N J M Birdsall; Frank P Bymaster; Christian Felder
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(31):10978-83.
2008: Anantha Shekhar; William Z Potter; Jeffrey Lightfoot; John Lienemann; Sanjay Dubé; Craig Mallinckrodt; Frank P Bymaster; David L McKinzie; Christian Felder
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
The American journal of psychiatry 2008;165(8):1033-9.
2006: Eleni T Tzavara; Frank P Bymaster; George Nomikos
The procholinergic effects of the atypical antipsychotic olanzapine are independent of muscarinic autoreceptor inhibition.
Molecular psychiatry 2006;11(7):619-21.
2006: Chad J Swanson; Kenneth W Perry; Susanne Koch-Krueger; Jason S Katner; Kjell A Svensson; Frank P Bymaster
Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat.
Neuropharmacology 2006;50(6):755-60.
2006: Kelly R Bales; Eleni T Tzavara; Su Wu; Mark R Wade; Frank P Bymaster; Steven M Paul; George Nomikos
Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody.
The Journal of clinical investigation 2006;116(3):825-32.
2006: Eleni T Tzavara; Frank P Bymaster; C D Overshiner; Richard J Davis; Kenneth W Perry; M Wolff; David L McKinzie; Jeffrey M Witkin; George Nomikos
Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.
Molecular psychiatry 2006;11(2):187-95.
2005: Kurt Rasmussen; Mark J Benvenga; Frank P Bymaster; David O Calligaro; Ilene R Cohen; Julie F Falcone; Susan K Hemrick-Luecke; Fionna M Martin; Nicholas Moore; Laura K Nisenbaum; John M Schaus; Sarah J Sundquist; David E Tupper; Todd R Wiernicki; David L Nelson
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
The Journal of pharmacology and experimental therapeutics 2005;315(3):1265-77.
2005: David T Wong; Kenneth W Perry; Frank P Bymaster
Case history: the discovery of fluoxetine hydrochloride (Prozac).
Nature reviews. Drug discovery 2005;4(9):764-74.
2005: Frank P Bymaster; Thomas C Lee; Mary Pat Knadler; Michael Detke; Smriti Iyengar
The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
Current pharmaceutical design 2005;11(12):1475-93.
2005: Walter Deberdt; Andrew Winokur; Patrizia Cavazzoni; Quynh N Trzaskoma; Christopher D Carlson; Frank P Bymaster; Karen Wiener; Michel Floris; Alan Breier
Amantadine for weight gain associated with olanzapine treatment.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2005;15(1):13-21.
2004: Carrie L Gick; Ginat W Mirowski; John S Kennedy; Frank P Bymaster
Treatment of glossodynia with olanzapine.
Journal of the American Academy of Dermatology 2004;51(3):463-5.
2004: Eleni T Tzavara; Frank P Bymaster; Richard J Davis; Mark R Wade; Kenneth W Perry; Jürgen Wess; David L McKinzie; Christian Felder; George Nomikos
M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(12):1410-2.
2004: Simi Vincent; Peter R Bieck; Emily M Garland; Corina Loghin; Frank P Bymaster; Bonnie K Black; Celedon Gonzales; William Z Potter; David Robertson
Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles.
Circulation 2004;109(25):3202-7.
2004: Susanne Koch; Kenneth W Perry; Frank P Bymaster
Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat.
Neuropharmacology 2004;46(2):232-42.
2003: Frank P Bymaster; E E Beedle; Jeremy Findlay; Peter T Gallagher; Joseph H Krushinski; Stephen Mitchell; D W Robertson; Dennis C Thompson; Louise Wallace; David T Wong
Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
Bioorganic & medicinal chemistry letters 2003;13(24):4477-80.
2003: Susanne Koch; Susan K Hemrick-Luecke; Linda K Thompson; David C Evans; Penny G Threlkeld; David L Nelson; Kenneth W Perry; Frank P Bymaster
Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.
Neuropharmacology 2003;45(7):935-44.
2003: Kirk W Johnson; Amy Clemens-Smith; George Nomikos; Richard Davis; Lee A Phebus; Harlan Shannon; Patrick Love; Ken Perry; Jason Katner; Frank P Bymaster; Hong Yu; Beth J Hoffman
In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors.
Annals of the New York Academy of Sciences 2003;1003():412-4.
2003: John S Kennedy; D Jeste; Christopher J Kaiser; S Golshan; Gerald A Maguire; Gary D Tollefson; Todd M Sanger; Frank P Bymaster; Bruce J Kinon; Martin Dossenbach; Julie A Gilmore; Alan Breier
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
International journal of geriatric psychiatry 2003;18(11):1013-20.
2003: Frank P Bymaster; Christian Felder; Eleni T Tzavara; George Nomikos; David O Calligaro; David L McKinzie
Muscarinic mechanisms of antipsychotic atypicality.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(7):1125-43.
2003: Stephan A Chalon; Luc-André Granier; François Vandenhende; Peter R Bieck; Frank P Bymaster; Melissa J Joliat; Christine Hirth; William Z Potter
Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(9):1685-93.
2003: Eleni T Tzavara; Frank P Bymaster; Christian Felder; Mark Wade; Jesus Gomeza; Jürgen Wess; David L McKinzie; George Nomikos
Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice.
Molecular psychiatry 2003;8(7):673-9.
2003: Maibritt B Andersen; Anders Fink-Jensen; Linda Peacock; Jes Gerlach; Frank P Bymaster; Jens A Lundbaek; Thomas Werge
The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(6):1168-75.
2003: Frank P Bymaster; Petra A Carter; Masahisa Yamada; Jesus Gomeza; Jürgen Wess; Susan E Hamilton; Neil M Nathanson; David L McKinzie; Christian Felder
Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity.
The European journal of neuroscience 2003;17(7):1403-10.
2003: Frank P Bymaster; David L McKinzie; Christian Felder; Jürgen Wess
Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system.
Neurochemical research 2003;28(3-4):437-42.
2003: Frank P Bymaster; Robert K McNamara; Pierre V Tran
New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.
Expert opinion on investigational drugs 2003;12(4):531-43.
2003: Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George Nomikos
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.
British journal of pharmacology 2003;138(4):544-53.
2003: Pierre V Tran; Frank P Bymaster; Robert K McNamara; William Z Potter
Dual monoamine modulation for improved treatment of major depressive disorder.
Journal of clinical psychopharmacology 2003;23(1):78-86.
2003: Jürgen Wess; Alokesh Duttaroy; Weilie Zhang; Jesus Gomeza; Yinghong Cui; T Miyakawa; Frank P Bymaster; L McKinzie; Christian Felder; Kathryn G Lamping; Frank M Faraci; Chuxia Deng; Masahisa Yamada
M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system.
Receptors & channels 2003;9(4):279-90.
2002: Susanne Koch; Kenneth W Perry; David L Nelson; Richard G Conway; Penny G Threlkeld; Frank P Bymaster
R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;27(6):949-59.
2002: Frank P Bymaster; Jason S Katner; David L Nelson; Susan K Hemrick-Luecke; Penny G Threlkeld; John H Heiligenstein; S Michelle Morin; Donald R Gehlert; Kenneth W Perry
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;27(5):699-711.
2002: Susan K Hemrick-Luecke; Frank P Bymaster; David C Evans; J Wess; Christian Felder
Muscarinic agonist-mediated increases in serum corticosterone levels are abolished in m(2) muscarinic acetylcholine receptor knockout mice.
The Journal of pharmacology and experimental therapeutics 2002;303(1):99-103.
2002: Amy C Porter; Frank P Bymaster; Neil DeLapp; Masahisa Yamada; Jürgen Wess; Susan E Hamilton; Neil M Nathanson; Christian Felder
M1 muscarinic receptor signaling in mouse hippocampus and cortex.
Brain research 2002;944(1-2):82-9.
2002: Amy C Porter; John-Michael Sauer; Michael D Knierman; Gerald Becker; Michael J Berna; Jingqi Bao; George Nomikos; Petra Carter; Frank P Bymaster; Andrea Baker Leese; Christian Felder
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
The Journal of pharmacology and experimental therapeutics 2002;301(3):1020-4.
2002: Stephan A Chalon; Peter R Bieck; David J Goldstein; Michael Detke; Frank P Bymaster; William Z Potter; Mark A Demitrack
The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;26(5):698-9; author reply 700-1.
2002: Frank P Bymaster; Christian Felder; Saeed Ahmed; David L McKinzie
Muscarinic receptors as a target for drugs treating schizophrenia.
Current drug targets. CNS and neurological disorders 2002;1(2):163-81.
2002: Frank P Bymaster; Wei Zhang; Petra A Carter; Janice Shaw; Eyassu Chernet; Lee A Phebus; David T Wong; Kenneth W Perry
Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex.
Psychopharmacology 2002;160(4):353-61.
2002: David T Wong; Frank P Bymaster
Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 2002;58():169-222.
2002: Frank P Bymaster; Christian Felder
Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents.
Molecular psychiatry 2002;7 Suppl 1():S57-63.
2001: Yansheng Du; Z Ma; Suizhen Lin; Richard Dodel; F Gao; Kelly R Bales; Lazaros C Triarhou; Eyassu Chernet; Kenneth W Perry; D L Nelson; S Luecke; Lee A Phebus; Frank P Bymaster; Steven M Paul
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(25):14669-74.
2001: Frank P Bymaster; LJ Dreshfield-Ahmad; Penny G Threlkeld; Janice L Shaw; L Thompson; David L Nelson; Susan K Hemrick-Luecke; David T Wong
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;25(6):871-80.
2001: John S Kennedy; Frank P Bymaster; Leslie M Schuh; David O Calligaro; George Nomikos; Christian Felder; M Bernauer; Bruce J Kinon; Robert W Baker; D Hay; H J Roth; Martin Dossenbach; C Kaiser; Charles Beasley; John H Holcombe; M B Effron; Alan Breier
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.
International journal of geriatric psychiatry 2001;16 Suppl 1():S33-61.
2001: John S Kennedy; A Zagar; Frank P Bymaster; George Nomikos; Paula T Trzepacz; Julie A Gilmore; Matthew D Rotelli; Alan Breier; Gary D Tollefson
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
International journal of geriatric psychiatry 2001;16 Suppl 1():S24-32.
2001: Masahisa Yamada; Kathryn G Lamping; Alokesh Duttaroy; Weilie Zhang; Yinghong Cui; Frank P Bymaster; David L McKinzie; Christian Felder; Chu-Xia Deng; Frank M Faraci; Jürgen Wess
Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(24):14096-101.
2001: Frank P Bymaster; Julie F Falcone; D Bauzon; John S Kennedy; Kathryn W Schenck; Neil DeLapp; Marlene L Cohen
Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.
European journal of pharmacology 2001;430(2-3):341-9.
2001: Frank P Bymaster; Petra A Carter; Neil DeLapp; David O Calligaro; Christian Felder
Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus in vivo.
Brain research 2001;916(1-2):165-71.
2001: Eleni T Tzavara; Kenneth W Perry; D E Rodriguez; Frank P Bymaster; George Nomikos
The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus.
European journal of pharmacology 2001;426(3):R3-4.
2001: Christian Felder; Amy C Porter; T L Skillman; L Zhang; Frank P Bymaster; Neil M Nathanson; Susan E Hamilton; Jesus Gomeza; Jürgen Wess; David L McKinzie
Elucidating the role of muscarinic receptors in psychosis.
Life sciences 2001;68(22-23):2605-13.
2001: Frank P Bymaster; Petra A Carter; L Zhang; Julie F Falcone; Peter stengel; Marlene L Cohen; Harlan E Shannon; Jesus Gomeza; Jürgen Wess; Christian Felder
Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice.
Life sciences 2001;68(22-23):2473-9.
2001: Jesus Gomeza; L Zhang; E Kostenis; Christian Felder; Frank P Bymaster; J Brodkin; Harlan Shannon; B Xia; Alokesh Duttaroy; Chu-Xia Deng; Jürgen Wess
Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice.
Life sciences 2001;68(22-23):2457-66.
2001: Thøger Rasmussen; Anders Fink-Jensen; Per Sauerberg; MD Swedberg; C Thomsen; MJ Sheardown; Lone Jeppesen; David O Calligaro; Neil DeLapp; CA Whitesitt; JS Ward; Harlan E Shannon; Frank P Bymaster
The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance.
Schizophrenia research 2001;49(1-2):193-201.
2001: Kenneth W Perry; Laura K Nisenbaum; Carolyn A George; Harlan E Shannon; Christian Felder; Frank P Bymaster
The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex.
Biological psychiatry 2001;49(8):716-25.
2001: Richard C Shelton; Gary D Tollefson; Mauricio Tohen; S Stahl; K S Gannon; Thomas G Jacobs; W R Buras; Frank P Bymaster; W Zhang; K A Spencer; Peter Feldman; Herbert Y Meltzer
A novel augmentation strategy for treating resistant major depression.
The American journal of psychiatry 2001;158(1):131-4.
2000: Christian Felder; Frank P Bymaster; J Ward; Neil DeLapp
Therapeutic opportunities for muscarinic receptors in the central nervous system.
Journal of medicinal chemistry 2000;43(23):4333-53.
2000: JS Street; WS Clark; K S Gannon; Jeffrey L Cummings; Frank P Bymaster; Roy Tamura; S J Mitan; Deborah L Kadam; Todd M Sanger; Peter Feldman; Gary D Tollefson; Alan Breier
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Archives of general psychiatry 2000;57(10):968-76.
2000: Wei Zhang; Kenneth W Perry; David T Wong; B D Potts; J Bao; Gary D Tollefson; Frank P Bymaster
Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;23(3):250-62.
2000: Thøger Rasmussen; Per Sauerberg; EB Nielsen; MD Swedberg; C Thomsen; MJ Sheardown; Lone Jeppesen; David O Calligaro; Neil DeLapp; CA Whitesitt; JS Ward; Harlan E Shannon; Frank P Bymaster; Anders Fink-Jensen
Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice.
European journal of pharmacology 2000;402(3):241-6.
2000: Harlan E Shannon; Kurt Rasmussen; Frank P Bymaster; J C Hart; Steven C Peters; MD Swedberg; Lone Jeppesen; MJ Sheardown; Per Sauerberg; Anders Fink-Jensen
Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
Schizophrenia research 2000;42(3):249-59.
2000: Frank P Bymaster; Julie F Falcone
Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium.
European journal of pharmacology 2000;390(3):245-8.
1999: Jesus Gomeza; L Zhang; E Kostenis; Christian Felder; Frank P Bymaster; J Brodkin; Harlan Shannon; B Xia; Chuxia Deng; Jürgen Wess
Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(18):10483-8.
1999: Harlan E Shannon; J C Hart; Frank P Bymaster; David O Calligaro; Neil DeLapp; Charles H Mitch; JS Ward; Anders Fink-Jensen; Per Sauerberg; Lone Jeppesen; MJ Sheardown; MD Swedberg
Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
The Journal of pharmacology and experimental therapeutics 1999;290(2):901-7.
1999: Lone Jeppesen; Preben Olesen; L Hansen; MJ Sheardown; C Thomsen; Thøger Rasmussen; A F Jensen; M S Christensen; Karin Rimvall; JS Ward; CA Whitesitt; David O Calligaro; Frank P Bymaster; Neil DeLapp; Christian Felder; Harlan E Shannon; Per Sauerberg
1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives.
Journal of medicinal chemistry 1999;42(11):1999-2006.
1999: Frank P Bymaster; David O Calligaro; Julie F Falcone
Arachidonic acid release in cell lines transfected with muscarinic receptors: a simple functional assay to determine response of agonists.
Cellular signalling 1999;11(6):405-13.
1999: BD Sawyer; Frank P Bymaster; David O Calligaro; Julie F Falcone; Charles H Mitch; JS Ward; CA Whitesitt; Harlan E Shannon
Direct pharmacological comparison of the muscarinic receptors mediating relaxation and contraction in the rabbit thoracic aorta.
General pharmacology 1999;32(4):445-52.
1999: Frank P Bymaster; K W Perry; David L Nelson; David T Wong; Kurt Rasmussen; Nicholas Moore; David O Calligaro
Olanzapine: a basic science update.
The British journal of psychiatry. Supplement 1999;(37):36-40.
1999: Frank P Bymaster; Harlan E Shannon; Kurt Rasmussen; Neil DeLapp; JS Ward; David O Calligaro; Charles H Mitch; CA Whitesitt; TS Ludvigsen; MJ Sheardown; MD Swedberg; Thøger Rasmussen; Preben Olesen; Lone Jeppesen; Per Sauerberg; Anders Fink-Jensen
Potential role of muscarinic receptors in schizophrenia.
Life sciences 1999;64(6-7):527-34.
1999: Wei Zhang; Frank P Bymaster
The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
Psychopharmacology 1999;141(3):267-78.
1998: Anders Fink-Jensen; P Kristensen; Harlan E Shannon; David O Calligaro; Neil DeLapp; CA Whitesitt; JS Ward; C Thomsen; T Rasmusseen; MJ Sheardown; Lone Jeppesen; Per Sauerberg; Frank P Bymaster
Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats.
Neuroreport 1998;9(15):3481-6.
1998: Per Sauerberg; Lone Jeppesen; Preben Olesen; Thøger Rasmussen; MD Swedberg; MJ Sheardown; Anders Fink-Jensen; C Thomsen; H Thøgersen; Karin Rimvall; JS Ward; David O Calligaro; Neil DeLapp; Frank P Bymaster; Harlan E Shannon
Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.
Journal of medicinal chemistry 1998;41(22):4378-84.
1998: Per Sauerberg; Lone Jeppesen; Preben Olesen; MJ Sheardown; Anders Fink-Jensen; Thøger Rasmussen; Karin Rimvall; Harlan E Shannon; Frank P Bymaster; Neil DeLapp; David O Calligaro; JS Ward; CA Whitesitt; C Thomsen
Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.
Bioorganic & medicinal chemistry letters 1998;8(20):2897-902.
1998: Frank P Bymaster; Harlan E Shannon; Kurt Rasmussen; Neil DeLapp; Charles H Mitch; JS Ward; David O Calligaro; TS Ludvigsen; MJ Sheardown; Preben Olesen; MD Swedberg; Per Sauerberg; Anders Fink-Jensen
Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .
European journal of pharmacology 1998;356(2-3):109-19.
1998: Frank P Bymaster; Petra A Carter; Steven C Peters; Wei Zhang; JS Ward; Charles H Mitch; David O Calligaro; CA Whitesitt; Neil DeLapp; Harlan E Shannon; Karin Rimvall; Lone Jeppesen; MJ Sheardown; Anders Fink-Jensen; Per Sauerberg
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.
Brain research 1998;795(1-2):179-90.
1998: Neil DeLapp; S Wu; R Belagaje; E Johnstone; S Little; Harlan Shannon; Frank P Bymaster; David O Calligaro; Charles H Mitch; CA Whitesitt; J Ward; MJ Sheardown; Anders Fink-Jensen; Lone Jeppesen; C Thomsen; Per Sauerberg
Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.
Biochemical and biophysical research communications 1998;244(1):156-60.
1998: X M Li; Kenneth W Perry; David T Wong; Frank P Bymaster
Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.
Psychopharmacology 1998;136(2):153-61.
1998: JS Ward; L Merritt; David O Calligaro; Frank P Bymaster; Harlan E Shannon; Charles H Mitch; CA Whitesitt; D Brunsting; MJ Sheardown; Preben Olesen; MD Swedberg; Lone Jeppesen; Per Sauerberg
1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.
Journal of medicinal chemistry 1998;41(3):379-92.
1998: Per Sauerberg; Preben Olesen; MJ Sheardown; Karin Rimvall; H Thøgersen; Harlan E Shannon; BD Sawyer; JS Ward; Frank P Bymaster; Neil DeLapp; David O Calligaro; MD Swedberg
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
Journal of medicinal chemistry 1998;41(1):109-16.
1997: Harlan E Shannon; MJ Sheardown; Frank P Bymaster; David O Calligaro; Neil DeLapp; J Gidda; Charles H Mitch; BD Sawyer; Peter stengel; JS Ward; David T Wong; Preben Olesen; PD Suzdak; Per Sauerberg; MD Swedberg
Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity.
The Journal of pharmacology and experimental therapeutics 1997;281(2):884-94.
1997: MD Swedberg; MJ Sheardown; Per Sauerberg; Preben Olesen; PD Suzdak; Kristian Tage Hansen; Frank P Bymaster; JS Ward; Charles H Mitch; David O Calligaro; Neil DeLapp; Harlan E Shannon
Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic.
The Journal of pharmacology and experimental therapeutics 1997;281(2):876-83.
1997: MJ Sheardown; Harlan E Shannon; MD Swedberg; PD Suzdak; Frank P Bymaster; Preben Olesen; Charles H Mitch; JS Ward; Per Sauerberg
M1 receptor agonist activity is not a requirement for muscarinic antinociception.
The Journal of pharmacology and experimental therapeutics 1997;281(2):868-75.
1997: Neil Bodick; Walter W Offen; Allan Levey; Neal R Cutler; S Gauthier; Andrew Satlin; Harlan E Shannon; Gary D Tollefson; Kurt Rasmussen; Frank P Bymaster; D J Hurley; W Z Potter; S M Paul
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Archives of neurology 1997;54(4):465-73.
1997: Charles H Mitch; T J Brown; Frank P Bymaster; David O Calligaro; Donna K Dieckman; L Merrit; Steven C Peters; Steven J Quimby; Harlan E Shannon; L A Shipley; JS Ward; K Hansen; Preben Olesen; Per Sauerberg; MJ Sheardown; MD Swedberg; PD Suzdak; B Greenwood
Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome.
Journal of medicinal chemistry 1997;40(4):538-46.
1997: Frank P Bymaster; Kurt Rasmussen; David O Calligaro; David L Nelson; Neil DeLapp; David T Wong; Nicholas Moore
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
The Journal of clinical psychiatry 1997;58 Suppl 10():28-36.
1997: Harlan E Shannon; DE Womer; Frank P Bymaster; David O Calligaro; N C DeLapp; Charles H Mitch; JS Ward; CA Whitesitt; MD Swedberg; MJ Sheardown; Anders Fink-Jensen; Preben Olesen; Karin Rimvall; Per Sauerberg
In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.
Life sciences 1997;60(13-14):969-76.
1996: Lars Farde; T Suhara; Christer Halldin; H Nybäck; Y Nakashima; Carl-Gunnar Swahn; Per Karlsson; N Ginovart; Frank P Bymaster; Harlan E Shannon; C Foged; PD Suzdak; Per Sauerberg
PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man.
Dementia (Basel, Switzerland) 1996;7(4):187-95.
1996: Frank P Bymaster; S K Hemrick-Luecke; Kenneth W Perry; R W Fuller
Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.
Psychopharmacology 1996;124(1-2):87-94.
1996: Frank P Bymaster; David O Calligaro; Julie F Falcone; R D Marsh; Nicholas Moore; N C Tye; Philip Seeman; David T Wong
Radioreceptor binding profile of the atypical antipsychotic olanzapine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;14(2):87-96.
1995: JS Ward; L Merritt; David O Calligaro; Frank P Bymaster; Harlan E Shannon; BD Sawyer; Charles H Mitch; J B Deeter; Steven C Peters; MJ Sheardown
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
Journal of medicinal chemistry 1995;38(18):3469-81.
1995: Per Sauerberg; Preben Olesen; MJ Sheardown; PD Suzdak; Harlan E Shannon; Frank P Bymaster; David O Calligaro; Charles H Mitch; JS Ward; MD Swedberg
Muscarinic agonists as analgesics. Antinociceptive activity versus M1 activity: SAR of alkylthio-TZTP's and related 1,2,5-thiadiazole analogs.
Life sciences 1995;56(11-12):807-14.
1995: J Baumgold; K Dyer; Julie F Falcone; Frank P Bymaster
Comparison of second-messenger responses to muscarinic receptor stimulation in M1-transfected A9 L cells.
Cellular signalling 1995;7(1):39-43.
1995: Harlan E Shannon; Frank P Bymaster; J C Hendrix; S J Quimby; Charles H Mitch
Novel alkoxy-oxazolyl-tetrahydropyridine muscarinic cholinergic receptor antagonists.
Psychopharmacology 1995;117(2):208-15.
1995: David T Wong; Frank P Bymaster; E A Engleman
Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication.
Life sciences 1995;57(5):411-41.
1995: David T Wong; Frank P Bymaster
Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors.
Advances in experimental medicine and biology 1995;363():77-95.
1994: Frank P Bymaster; David T Wong; Charles H Mitch; JS Ward; David O Calligaro; Darryle D Schoepp; Harlan E Shannon; MJ Sheardown; Preben Olesen; PD Suzdak
Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
The Journal of pharmacology and experimental therapeutics 1994;269(1):282-9.
1994: Harlan E Shannon; Frank P Bymaster; David O Calligaro; B Greenwood; Charles H Mitch; BD Sawyer; JS Ward; David T Wong; Preben Olesen; MJ Sheardown
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
The Journal of pharmacology and experimental therapeutics 1994;269(1):271-81.
1993: Frank P Bymaster; I Heath; J C Hendrix; Harlan E Shannon
Comparative behavioral and neurochemical activities of cholinergic antagonists in rats.
The Journal of pharmacology and experimental therapeutics 1993;267(1):16-24.
1993: David T Wong; Frank P Bymaster; L R Reid; D A Mayle; J H Krushinski; D W Robertson
Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1993;8(4):337-44.
1993: David T Wong; P G Threlkeld; Frank P Bymaster
Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites.
Arzneimittel-Forschung 1993;43(4):409-12.
1993: Harlan E Shannon; BD Sawyer; K G Bemis; Frank P Bymaster; I Health; Charles H Mitch; JS Ward
Muscarinic M1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens.
European journal of pharmacology 1993;232(1):47-57.
1993: David T Wong; Frank P Bymaster; D A Mayle; L R Reid; J H Krushinski; D W Robertson
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1993;8(1):23-33.
1992: JS Ward; L Merritt; V J Klimkowski; M L Lamb; Charles H Mitch; Frank P Bymaster; BD Sawyer; Harlan E Shannon; Preben Olesen; T Honoré
Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore.
Journal of medicinal chemistry 1992;35(22):4011-9.
1992: A I Sacaan; Frank P Bymaster; Darryle D Schoepp
Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine.
Journal of neurochemistry 1992;59(1):245-51.
1992: Per Sauerberg; Preben Olesen; S Nielsen; S Treppendahl; MJ Sheardown; T Honoré; Charles H Mitch; JS Ward; A J Pike; Frank P Bymaster
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
Journal of medicinal chemistry 1992;35(12):2274-83.
1988: David T Wong; D W Robertson; Frank P Bymaster; J H Krushinski; L R Reid
LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug.
Life sciences 1988;43(24):2049-57.
1986: Frank P Bymaster; L R Reid; C L Nichols; E C Kornfeld; David T Wong
Elevation of acetylcholine levels in striatum of rat brain by LY163502, trans-(-)-5,5a,6,7,8,9a,10-octahydro-6-propylpyrimido less than 4,5-g greater than quinolin-2-amine dihydrochloride, a potent and stereospecific dopamine (D2) agonist.
Life sciences 1986;38(4):317-22.
1986: Mitchell I Steinberg; J K Smallwood; D R Holland; Frank P Bymaster; K G Bemis
Hemodynamic and electrocardiographic effects of fluoxetine and its major metabolite, norfluoxetine, in anesthetized dogs.
Toxicology and applied pharmacology 1986;82(1):70-9.
1985: David T Wong; L R Reid; Frank P Bymaster; P G Threlkeld
Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmitter receptors.
Journal of neural transmission 1985;64(3-4):251-69.
1984: David T Wong; P G Threlkeld; Frank P Bymaster; R F Squires
Saturable binding of 35S-t-butylbicyclophosphorothionate to the sites linked to the GABA receptor and the interaction with GABAergic agents.
Life sciences 1984;34(9):853-60.
1983: David T Wong; Frank P Bymaster; L R Reid; P G Threlkeld
Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors.
Biochemical pharmacology 1983;32(7):1287-93.
1983: David T Wong; Frank P Bymaster; L R Reid; R W Fuller; K W Perry; E C Kornfeld
Effect of a stereospecific D2-dopamine agonist on acetylcholine concentration in corpus striatum of rat brain.
Journal of neural transmission 1983;58(1-2):55-67.
1982: David T Wong; P G Threlkeld; K L Best; Frank P Bymaster
A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain.
The Journal of pharmacology and experimental therapeutics 1982;222(1):61-5.
1980: David T Wong; Frank P Bymaster; P T Lane; D Kau; N J Bach; E C Kornfeld
Binding of [3H]pergolide mesylate to dopamine receptors of mammalian brains.
Research communications in chemical pathology and pharmacology 1980;30(2):195-210.
1980: David T Wong; Frank P Bymaster; L R Reid
Competitive inhibition of catecholamine uptake in synaptosomes of rat brain by rigid bicyclo-octanes.
Journal of neurochemistry 1980;34(6):1453-8.